Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Urologic oncology: Seminars and original investigations, 42.2024, 11, S. 371.e11-371.e18
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2024
- Urheber
- DOI
-
10.1016/j.urolonc.2024.06.016
- URN
-
urn:nbn:de:hebis:30:3-866080
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wenzel, Mike
- Höh, Robert Benedikt
- Kopf, Philipp
- Siech, Carolin
- Humke, Clara Julia
- Würnschimmel, Christoph
- Steuber, Thomas
- Graefen, Markus
- Preißer, Felix
- Traumann, Miriam
- Banek, Séverine
- Kluth, Luis
- Chun, Felix
- Mandel, Philipp
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2024
Ähnliche Objekte (12)
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Public Education, Accountability, and Yardstick Competition in a Federal System
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Wertigkeit der Schnellschnitt-gesteuerten Nerverhaltung : Ergebnisse von 11.069 konsekutiven radikalen Prostatektomien
Der Einfluss von Rehabilitationsmaßnahmen auf die Inkontinenz nach radikaler Prostatektomie bei Prostatakarzinompatienten
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Public Education, Accountability, and Yardstick Competition in a Federal System
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Wertigkeit der Schnellschnitt-gesteuerten Nerverhaltung : Ergebnisse von 11.069 konsekutiven radikalen Prostatektomien
Der Einfluss von Rehabilitationsmaßnahmen auf die Inkontinenz nach radikaler Prostatektomie bei Prostatakarzinompatienten
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Public Education, Accountability, and Yardstick Competition in a Federal System
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients
Wertigkeit der Schnellschnitt-gesteuerten Nerverhaltung : Ergebnisse von 11.069 konsekutiven radikalen Prostatektomien